0001209191-17-006695.txt : 20170201
0001209191-17-006695.hdr.sgml : 20170201
20170201162230
ACCESSION NUMBER: 0001209191-17-006695
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170131
FILED AS OF DATE: 20170201
DATE AS OF CHANGE: 20170201
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ANAPTYSBIO INC
CENTRAL INDEX KEY: 0001370053
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 203828755
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10421 PACIFIC CENTER COURT, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-362-6295
MAIL ADDRESS:
STREET 1: 10421 PACIFIC CENTER COURT, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: ANAPTYS BIOSCIENCES INC
DATE OF NAME CHANGE: 20060724
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Novo A/S
CENTRAL INDEX KEY: 0001388325
STATE OF INCORPORATION: G7
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37985
FILM NUMBER: 17565189
BUSINESS ADDRESS:
STREET 1: TUBORG HAVNEVEJ 19
CITY: HELLERUP
STATE: G7
ZIP: 2900
BUSINESS PHONE: 45 8824 8824
MAIL ADDRESS:
STREET 1: TUBORG HAVNEVEJ 19
CITY: HELLERUP
STATE: G7
ZIP: 2900
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-01-31
0
0001370053
ANAPTYSBIO INC
ANAB
0001388325
Novo A/S
TUBORG HAVNEVEJ 19
HELLERUP
G7
2900
DENMARK
0
0
1
0
Common Stock
2017-01-31
4
C
0
1428571
A
1428571
D
Common Stock
2017-01-31
4
C
0
486820
A
1915391
D
Common Stock
2017-01-31
4
C
0
312986
A
2228377
D
Common Stock
2017-01-31
4
C
0
673454
A
2901831
D
Common Stock
2017-01-31
4
X
0
81673
A
2983504
D
Common Stock
2017-01-31
4
P
0
50000
15.00
A
3033504
D
Series B Preferred Stock
2017-01-31
4
C
0
1428571
0.00
D
Common Stock
1428571
0
D
Series C Preferred Stock
2017-01-31
4
C
0
486820
0.00
D
Common Stock
486820
0
D
Series C-1 Preferred Stock
2017-01-31
4
C
0
312986
0.00
D
Common Stock
312986
0
D
Series D Preferred Stock
2017-01-31
4
C
0
673454
0.00
D
Common Stock
673454
0
D
Series C Preferred Stock Warrant (Right to Buy)
4.55
2017-01-31
4
X
0
117235
0.00
D
2018-11-04
Common Stock
117235
0
D
The Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock (the "Preferred Stock") had no expiration date and was convertible at any time at the holder's election. Immediately prior to the closing of the Issuer's initial public offering (the "IPO Closing"), the Preferred Stock automatically converted on a one-for-one basis for no additional consideration into common stock.
Immediately prior to the IPO Closing, the warrant became exercisable for shares of common stock. The shares acquired upon exercise of the warrant were acquired through a net exercise procedure in accordance with the terms of the warrant and did not involve any sale of shares. All shares received upon such exercise are subject to a lock-up agreement between the Reporting Person and the underwriters.
Represents a purchase from the underwriters in the Issuer's initial public offering.
Novo A/S is a Danish limited liability company. The board of directors of Novo A/S (the "Novo Board"), currently comprised of Sten Scheibye, Goran Ando, Jeppe Christiansen, Steen Riisgaard and Per Wold-Olsen, has shared investment and voting control over the securities of the Issuer held by Novo A/S (the "Shares") and may exercise such control only with the support of a majority of the Novo Board. As such, no individual member of the Novo Board is deemed to hold any beneficial ownership or reportable pecuniary interest in the Shares.
/s/ Peter Haahr, Chief Financial Officer of Novo A/S
2017-01-31